Scotiabank analyst Louise Chen initiated coverage with a Buy rating on AbbVie (ABBV – Research Report) yesterday and set a price target of ...

In a report released today, Vamil Divan from Guggenheim maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of $214.00. The company’s shares opened today at $172.57.

Ross, M.D., Ph.D., vice president, early oncology research and development, AbbVie. "By harnessing the latest scientific breakthroughs in translational research, we are advancing novel therapeutic ...

AbbVie. "This exciting milestone demonstrates our commitment to ongoing research and expanding indications in areas of high unmet need to help patients achieve better outcomes, including sustained ...

Joey Jordison ’s family have shared the drummer’s original design of the Slipknot logo.

A multibillion-dollar partnership between AbbVie and Genmab risks being soured by a lawsuit claiming misappropriation of trade secrets. Specifically, it focuses on the use of disaccharides to ...

DelveInsight's "XADAGO/EQUFINA Market Size, Forecast, and Market Insight Report" highlights the details around XADAGO/EQUFINA ...

Ross, M.D., Ph.D., vice president, early oncology research and development, AbbVie. "By harnessing the latest scientific breakthroughs in translational research, we are advancing novel therapeutic ...

About AbbVie in Rheumatology For more than 20 years, AbbVie has been dedicated to improving care for people living with rheumatic diseases. Anchored by a longstanding commitment to discovering and ...